Digitoxin
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C41H64O13 |
Molar mass | 764.939 g/mol |
WikiDoc Resources for Digitoxin |
Articles |
---|
Most recent articles on Digitoxin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Digitoxin at Clinical Trials.gov Clinical Trials on Digitoxin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Digitoxin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Digitoxin Discussion groups on Digitoxin Directions to Hospitals Treating Digitoxin Risk calculators and risk factors for Digitoxin
|
Healthcare Provider Resources |
Causes & Risk Factors for Digitoxin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Digitoxin is a cardiac glycoside. It has similar structure and effects to digoxin (though the effects are longer-lasting). Unlike digoxin (which is eliminated from the body via the kidneys), it is eliminated via the liver, so could be used in patients with poor or erratic kidney function. However, it is now rarely used in current Western medical practice. While several controlled trials have shown digoxin to be effective in a proportion of patients treated for heart failure, the evidence base for digitoxin is not as strong, although it is presumed to be similarly effective.[1]
Toxicity
Digitoxin exhibits similar toxic effects to the more commonly used digoxin, namely: anorexia, nausea, vomiting, diarrhea, confusion, visual disturbances, and cardiac arrhythmias. Antidigoxin antibody fragments, the specific treatment for digoxin poisoning, are also effective in serious digitoxin toxicity.[2]
History
The first description of the use of foxglove dates back to 1775.[3] For quite some time, the active compound was not isolated. Oswald Schmiedeberg was able to obtain a pure sample in 1875. The modern therapeutic use of this molecule was made possible by the works of the pharmacist and the French chemist Claude-Adolphe Nativelle (1812-1889). The first structural analysis was done by Adolf Otto Reinhold Windaus in 1925, but the full structure with an exact determination of the sugar groups was not accomplished until 1962.[4][5]
References
- ↑ Belz, G. G.; Breithaupt-Grögler, K.; Osowski, U. (2001). "Treatment of congestive heart failure—current status of use of digitoxin". European Journal of Clinical Investigation. 31 (Suppl 2): 10–17. doi:10.1046/j.1365-2362.2001.0310s2010.x. PMID 11525233.
- ↑ Kurowski, V.; Iven, H.; Djonlagic, H. (1992). "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies". Intensive Care Medicine. 18 (7): 439–442. doi:10.1007/BF01694351. PMID 1469187.
- ↑ Withering, William (1785). An Account of the Foxglove and Some of its Medical Uses: With Practical Remarks on Dropsy and other Diseases.
- ↑ PMID 18127991 (PMID 18127991)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Sneader, Walter (2005). Drug discovery: A history. p. 107. ISBN 978-0-471-89980-8.
- Johansson, S.; Lindholm, P.; Gullbo, J.; Larsson, R.; Bohlin, L.; Claeson, P. (2001). "Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells". Anticancer Drugs. 12 (5): 475–483. doi:10.1097/00001813-200106000-00009. PMID 11395576.
- Hippius, M.; Humaid, B.; Sicker, T.; Hoffmann, A.; Göttler, M.; Hasford, J. (2001). "Adverse drug reaction monitoring--digitoxin overdosage in the elderly". International Journal of Clinical Pharmacology and Therapeutics. 39 (8): 336–343. PMID 11515708.
- Haux, J.; Klepp, O.; Spigset, O.; Tretli, S. (2001). "Digitoxin medication and cancer; case control and internal dose-response studies" (pdf). BMC Cancer. 1: 11. doi:10.1186/1471-2407-1-11. PMC 48150. PMID 11532201.
- Srivastava, M.; Eidelman, O.; Zhang, J.; Paweletz, C.; Caohuy, H.; Yang, Q.; Jacobson, K. A.; Heldman, E.; Huang, W.; Jozwik, C.; Pollard, B. S.; Pollard, H. B. (2004). "Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells". Proceedings of the National Academy of Science of the United States of America. 101 (20): 7693–7698. doi:10.1073/pnas.0402030101. PMC 419668. PMID 15136726.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with incomplete PMID references
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Glycosides
- Cardiology
- Cardenolides
- Drugs